Gilead UK & Ireland 2023 Oncology Fellowship and Medical Grants Programme now open

Gilead UK & Ireland 2023 Oncology Fellowship and Medical Grants Programme now open

=======

Could your project ultimately improve patient care in the field of oncology? We’re here to fund projects like yours.

The Gilead UK & Ireland Oncology Fellowship and Medical Grants Programme (GFP) is a medical grants funding stream looking to support projects and initiatives which ultimately lead to an improvement in oncology care. Overall, the Programme has funded nearly 350 projects since 2008.

The 2023 Programme is now open and accepting applications until 25th August.

Programme funding can be used to fund a variety of projects, including but not limited to:

  • Audits or registry reviews assessing patient profiles, disease outcomes and treatment patterns
  • Setting up new infrastructure for better diagnosis or detection of disease, or prediction or monitoring of safety and efficacy outcomes to treatment including increased disease awareness in primary care and amongst members of the public
  • Establishing novel patient support programmes or tools
  • New protocols to facilitate improved efficiency in patient care pathways
  • Frameworks to improve monitoring of patient-reported outcome measures or quality of life instruments or educational tools for patients and careers

 

Projects designed to tackle inequalities in cancer care amongst patient groups with poorer outcomes and/or access to care are particularly welcome. Priority will be given to those projects that focus on patients with breast cancer, urothelial cancer and lung cancer.

If you are interested in learning about the GFP or the application process, or to check if your project is eligible for a grant and apply, please visit the Gilead UK and Ireland website here. For general enquiries or questions about an application, please email [email protected] for support.

Date of preparation: July 2023

Code: UK-UNB-4110

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article